Lutonix药物涂层球囊在真实世界股腘动脉外周动脉疾病患者中的长期疗效:SAFE-DCB美国注册研究结果
SAFE-DCB美国注册研究为前瞻性、多中心、单臂真实世界研究,纳入1005例股腘动脉病变患者,评估Lutonix 035药物涂层球囊的3年结局。12个月主要通畅率为83.7%,36个月免于靶病变血运重建率为74.4%,36个月免于大截肢率为95.6%,显示持续安全有效。
要点
- Lutonix 035 DCB在真实世界股腘动脉病变中3年免于TLR率达74.4%。
- 12个月主要通畅率83.7%,36个月免于TVR率69.5%。
- 36个月免于靶肢体大截肢率95.6%,围手术期安全事件率低。
核心结论
- SAFE-DCB美国注册研究显示Lutonix 035 DCB治疗股腘动脉病变在3年内具有持续的安全性和有效性。
研究设计与样本
- 前瞻性、多中心、单臂真实世界注册研究,在美国74个中心纳入1005例受试者,按方案分析966例患者(平均年龄69.1岁,56.7%男性),共治疗1237处靶病变。
主要发现
- 12个月主要通畅率(Kaplan-Meier估计)为83.7%。
- 免于TLR率12个月为88.6%,24个月为75.7%,36个月为74.4%。
- 36个月免于TVR率(Kaplan-Meier估计)为69.5%。
- 30天免于主要安全事件率为98.2%。
- 36个月免于靶肢体大截肢率为95.6%。
关键数值与推荐
- 93.3%的靶病变为原发病变,85.2%位于股浅动脉,88%伴有轻至重度钙化。
- 低 bailout 支架植入率为1.7%。
临床怎么用
- 在偏好「leave nothing behind」策略时,Lutonix 035 DCB可作为股腘动脉病变的可行选择,支持其真实世界应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several studies have demonstrated the efficacy of paclitaxel drug-coated balloons (DCBs) for the treatment of femoropopliteal (FP) lesions in patients with peripheral artery disease (PAD). Despite the available evidence, long-term real-world efficacy data are limited. OBJECTIVES: To report the 3-year outcomes of the prospective, multicenter, single-arm real-world registry conducted in the United States, assessing the clinical use of the Lutonix 035 DCB in arteries of the superficial femoral artery (SFA) and popliteal artery (PA). METHODS: In the SAFE-DCB US Registry, a total of 1005 subjects at 74 investigational sites were treated with the Lutonix 035 DCB and were followed up to 36 months. The per protocol included 966 patients (mean age 69.1 years; 56.7% male). A total of 1237 target lesions were treated, in which 93.3% were de novo, 85.2% were located in the SFA, and 88% had mild-to-severe calcification. Forty-five percent of the patients were Rutherford 3, and 35.1% had critical limb-threatening ischemia. The primary efficacy endpoint is target lesion revascularization (TLR) at 12 months. Secondary endpoints included rate of primary patency at 12 months and freedom from TLR and freedom from target vessel revascularization (TVR) evaluated through 36 months. The safety endpoints evaluated through 36 months were freedom from the composite of device- and/or procedure-related perioperative (≤30 day) death, TVR, and freedom from major amputation of the target limb. RESULTS: Primary patency at 12 months post-index procedure by Kaplan-Meier estimates was 83.7%. Freedom from TLR at 12 months was 88.6%, 75.7% at 24 months, and 74.4% at 36 months. At 36 months, freedom from TVR post-index procedure by Kaplan-Meier estimates was 69.5%. Freedom from primary safety events at 30 days was 98.2%. Freedom from composite of all-cause perioperative (≤30 day) death and from the following: index limb amputation, index limb reintervention, and index-limb-related death by Kaplan-Meier estimates at 12 months was 80.8%, at 24 months 67.4% and 58.4% at 36 months. Freedom from major amputation of the target limb at 36 months was 95.6%. CONCLUSION: The results from the SAFE-DCB US Registry for femoral popliteal (FP) disease demonstrated sustained safety and efficacy over 3 years following the Lutonix 035 DCB intervention.Clinical ImpactThis prospective real-world population study supports long-term clinical outcomes of Lutonix and provides meaningful insights into the sustained efficacy of drug-coated balloon (DCB) therapy in real-world femoropopliteal population. The low-bailout stenting rate (1.7%), and the 36-month sustained Freedom from target lesion revascularization rate (74.4%) supporting DCB usage when a "leave nothing behind" approach is favored. Furthermore, these results reinforce the effectiveness of DCBs in the endovascular treatment peripheral artery disease.
引用
- Shammas NW, Franga D, Moore E, et al. Long-Term Efficacy of Lutonix in a Real-World Femoropopliteal Patients With Peripheral Arterial Disease: Insights From the SAFE-DCB US Registry. J Endovasc Ther. 2026. PMID: 42366790. doi:10.1177/15266028261453224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。